Genetic Analysis System Will Use Nanoscale Whole Genome Imaging Technology

Nanoscale whole genome imaging and analytic platforms are being developed for applications in clinical genetics, cancer diagnostics, and other biomedical applications. Nanosystems technology provides fast, comprehensive, and low-cost analysis of genomic, epigenomic, and proteomic information with sensitivity at the single cell/single molecule level.

Agilent Technologies Inc. (Santa Clara, CA, USA) and BioNanomatrix Inc. (Philadelphia, PA, USA) have entered into a collaboration to develop a genetic analysis system. BioNanomatrix is developing technology that enables nanoscale single molecule identification and analysis of the entire genome, delivering single-molecule sensitivity in a highly parallel format. Agilent will provide the measurement instrumentation platform for the system.

BioNanomatrix's analytic platform has the potential to provide rapid, comprehensive, and cost-effective ultra-high resolution analyses of DNA. The two companies intend to collaborate closely in the development of an integrated system and applications.

"BioNanomatrix's unique nanoscale whole genome imaging and analysis technology, with sensitivity at the level of the single molecule, has the potential to enable a number of important new applications for life-sciences research and clinical medicine,” said Nick Roelofs, vice president and general manager of the life-sciences solutions unit at Agilent.

Dr. Michael Boyce-Jacino, CEO of BioNanomatrix said, "We now have a partner with strong life sciences expertise and capabilities committed to working with us to develop key life- sciences applications, such as assays for genotoxicity and cytogenetics, as well as potentially DNA sequencing.”


Related Links:
Agilent
BioNanomatrix